Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2
Maowu Luo, … , Yingfei Wang, Weibo Luo
Maowu Luo, … , Yingfei Wang, Weibo Luo
Published January 23, 2024
Citation Information: J Clin Invest. 2024;134(6):e171166. https://doi.org/10.1172/JCI171166.
View: Text | PDF
Research Article

ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2

  • Text
  • PDF
Abstract

Breast cancer stem cells (BCSCs) mitigate oxidative stress to maintain their viability and plasticity. However, the regulatory mechanism of oxidative stress in BCSCs remains unclear. We recently found that the histone reader ZMYND8 was upregulated in BCSCs. Here, we showed that ZMYND8 reduced ROS and iron to inhibit ferroptosis in aldehyde dehydrogenase–high (ALDHhi) BCSCs, leading to BCSC expansion and tumor initiation in mice. The underlying mechanism involved a two-fold posttranslational regulation of nuclear factor erythroid 2–related factor 2 (NRF2). ZMYND8 increased stability of NRF2 protein through KEAP1 silencing. On the other hand, ZMYND8 interacted with and recruited NRF2 to the promoters of antioxidant genes to enhance gene transcription in mammospheres. NRF2 phenocopied ZMYND8 to enhance BCSC stemness and tumor initiation by inhibiting ROS and ferroptosis. Loss of NRF2 counteracted ZMYND8’s effects on antioxidant genes and ROS in mammospheres. Interestingly, ZMYND8 expression was directly controlled by NRF2 in mammospheres. Collectively, these findings uncover a positive feedback loop that amplifies the antioxidant defense mechanism sustaining BCSC survival and stemness.

Authors

Maowu Luo, Lei Bao, Yuanyuan Xue, Ming Zhu, Ashwani Kumar, Chao Xing, Jennifer E. Wang, Yingfei Wang, Weibo Luo

×

Figure 9

ZMYND8 is a direct NRF2 target gene.

Options: View larger image (or click on image) Download as PowerPoint

ZMYND8 is a direct NRF2 target gene.
(A) Correlation analysis between Z...
(A) Correlation analysis between ZMYND8 and NFE2L2 mRNAs in human breast tumors from TCGA cohort. (B and C) Analysis of ZMYND8 mRNA in MDA-MB-231-SC, (B) and MCF-7-SC, (C) NRF2 KO1, and NRF2 KO2 mammospheres (n = 3–4). (D) Analysis of ZMYND8 and NRF2 protein levels in MDA-MB-231-SC and MCF-7-SC, NRF2 KO1, and NRF2 KO2 cells after MG132 (10 μM) treatment (n = 3). (E) NRF2 enrichment at the ZMYND8 promoter in MDA-MB-231 mammospheres (top). The ZMYND8 ARE sequence is shown at the bottom. Rep, replicate; AREmu, ARE mutant. (F and G) Luciferase reporter assay in HEK293T cells cotransfected with indicated plasmids. The firefly/Renilla luciferase activity is quantified (F) (n = 4). Analysis of NRF2 protein levels (G). Data represent mean ± SEM. P value was determined by using 1-way ANOVA corrected with Dunnett’s test (B and C) and 2-way ANOVA corrected with Tukey’s test (F). ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts